02:00 Thu 22 Oct 2020
IXICO plc - Further Huntington’s disease contracts
IXICO plc
("IXICO" or the "Company")
Further Huntington's disease contracts
Additional Huntington's disease contracts with new and existing large pharma clients
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has secured new contracts in Huntington's disease (HD) clinical trials.
The new contracts include retrospective analysis of data sets for three Natural History Studies in Huntington's disease with a new large pharma customer and a multicentre, open-label Phase II study in Huntington's disease with an existing large pharma customer.
Whilst these contracts to support HD clinical trials are not to the same scale as the
For further information please contact:
IXICO plc |
+44 (0)20 3763 7498 |
|||
|
|
|||
|
|
|||
Cenkos Securities PLC (Nominated adviser and sole broker) |
+44 (0)20 7397 8900 |
|||
|
|
|||
Michael F Johnson / |
|
|||
|
|
|||
Walbrook PR Ltd |
+44 (0)20 7933 8780 |
|||
|
||||
|
|
|||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE